Shareholder Class Action 

CHICAGO — Shareholders say in a federal class action that they lost more than $100 million when Abbvie biopharmaceuticals announced it was buying back up to $7.5 billion of its own shares in a modified Dutch auction at $105 a share, but after the market closed, revealed that the price was only $103 a share.

%d bloggers like this: